Germline whole genome sequencing in pediatric oncology in Denmark:Practitioner perspectives by Byrjalsen, Anna et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Germline whole genome sequencing in pediatric oncology in Denmark
Practitioner perspectives
Byrjalsen, Anna; Stoltze, Ulrik Kristoffer; Castor, Anders; Wahlberg, Ayo
Published in:
Molecular Genetics & Genomic Medicine
DOI:
https://doi.org/10.1002/mgg3.1276
Publication date:
2020
Citation for published version (APA):
Byrjalsen, A., Stoltze, U. K., Castor, A., & Wahlberg, A. (2020). Germline whole genome sequencing in pediatric
oncology in Denmark: Practitioner perspectives. Molecular Genetics & Genomic Medicine, 8(8), e1276.
https://doi.org/10.1002/mgg3.1276
Download date: 10. sep.. 2020
 1 
 
Germline whole genome sequencing in pediatric 
oncology in Denmark – practitioner perspectives 
Running title: Practitioner perspectives on WGS 
Authors: 
Anna Byrjalsen, Department of Clinical Genetics & Department of Pediatric and Adolescent 
Medicine, Copenhagen University Hospital Rigshospitalet, Denmark 
Ulrik Kristoffer Stoltze, Department of Pediatric and Adolescent Medicine, Copenhagen University 
Hospital Rigshospitalet, Denmark 
Anders Castor, Department of Paediatrics, Skaane University Hospital, Sweden 
Ayo Wahlberg, Department of Anthropology, University of Copenhagen, Denmark 
Corresponding author: Anna Byrjalsen, Department of Clinical Genetics & Department of Pediatric 
and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 
Copenhagen east, Denmark. E-mail: anna.byrjalsen@regionh.dk 
Acknowledgement: We would like to acknowledge all the healthcare professionals who have 
taken out valuable time to speak to and fill out questionnaires for us. We would also like to thank 
The Danish Childhood Cancer Foundation, Engineer Otto Christensens foundation, Aase and Ejnar 
Danielsens Foundation and the Capital Regions’ Health Research Foundation for supporting this 
research.   
Conflicts of interest: The authors declare no conflicts of interest. 
Data availability statement: The data supporting the findings of this study are available within this 
paper. 
 
 
 2 
 
Abstract  
Background 
With the implementation of a research project providing whole genome sequencing (WGS) to all 
pediatric cancer patients in Denmark (2016-2019), we sought to investigate healthcare 
professionals’ views on WGS as it was actively being implemented in pediatric oncology. 
Methods 
Semi-structured interviews were carried out with pediatric oncologists, clinical geneticists and 
research coordinating nurses (n=17), followed by content analysis of transcribed interviews. 
Interviews were supplemented by ethnographic observations on Danish pediatric oncology wards. 
Additionally, questionnaires were distributed to healthcare professionals concerning when they 
found it appropriate to approach families regarding WGS. The response rate was 74%. 
Results 
Healthcare professionals see imbalances in doctor-patient relations, especially the double-role 
doctors have as clinicians and researchers. Some were concerned that it might not be possible to 
obtain meaningful informed consent from all families following diagnosis. Still, 94% of respondents 
found it acceptable to approach families during the first four weeks from the child’s diagnosis. 
Views on the utility of WGS, treatment adaptation and surveillance differed among interviewees.  
Conclusion 
Overall, healthcare professionals see dilemmas arising from WGS in the pediatric oncology clinic, 
and some advocate for further educational sessions with families and healthcare professionals. 
Despite concerns, healthcare professionals overwhelmingly supported early approach of families 
regarding WGS. Interviewees disagree on the benefits of surveillance based on genetic findings. 
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Introduction  
Pediatric oncology is a research-intensive medical specialty in Denmark, as it is globally. Societal 
attention, ear-marked research funds and specialized research laboratories have contributed to 
the establishment of extensive research programs across Denmark’s four pediatric oncology 
centers. And so, while medical practitioners on pediatric oncology wards are focused on providing 
the best possible treatment and care for their patients, the integration of research within the clinic 
shapes daily treatment routines and patient treatment trajectories. Oncologists are tasked with 
introducing families to various ongoing research projects, and clinic nurses are asked to help 
collect samples, forms and questionnaires for these projects. Such efforts must co-exist with their 
primary responsibility; caring for their patients, and finding the right balance can be a challenge 
especially when some patients are eligible for five to ten projects at the time of inclusion. 
Indeed, clinical care and research are now so intertwined that Cambrosio and colleagues have 
argued that a longstanding tradition for translational research has contributed to what they see as 
“oncology’s fading boundary between research and care” (1).  
They argue that the field of genomics has accelerated within oncological research, fueled by 
‘personalized medicine’ research agendas and falling sequencing costs. As a direct consequence, a 
string of qualitative studies has in recent years investigated medical practitioner perspectives on 
whole genome sequencing (WGS) (2, 3, 4, 5). While each of these studies have prospectively asked 
practitioners about their views at a time when “WGS may soon play an important role in primary 
and specialty care” (2), our study is different. We have investigated practitioner perspectives on 
WGS at a time when it is being actively integrated within an entire nationwide specialty, namely 
pediatric oncology in Denmark, through the Sequencing Tumor and Germline DNA—Implications 
and National Guidelines (STAGING) project, providing WGS to all newly diagnosed pediatric cancer 
patients in Denmark. STAGING maps frequency of cancer predisposition syndromes in a 
consecutive, national cohort of children with cancer. This knowledge is used for treatment 
adaptation, implementing relevant surveillance measures and family planning. The present study 
was designed and carried out by an anthropologist (AW) and a clinical geneticist (AB) to 
investigate how pediatric oncologists, clinical geneticists and nurses perceived, reflected on and 
reacted to the introduction of WGS in the clinic in real time through a research project and when 
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they found it appropriate to approach families about WGS research. As we will show in what 
follows, this introduction has not been without friction, raising both ethical and practical 
dilemmas, yet it is feasible to implement, and healthcare professionals are overall supportive of 
WGS research (6, 7). 
 
Material and Methods 
The qualitative part of the present study is based on semi-structured interviews carried out with 
12 pediatric oncologists, 3 clinical geneticists and 2 research coordinator nurses by the 
anthropologist (n=17). AB has been responsible for recruiting over 240 families into the STAGING 
project and has had direct interactions with treating physicians, nurses, laboratory technicians and 
research coordinators over the last years (2016-2019). ABs direct experiences of recruiting for 
STAGING and AWs participation in various debates and discussions at seminars form an important 
backdrop to the interview data.  
All interviewed healthcare practitioners have played a role in STAGING, whether as treating 
physician or directly involved in STAGING (recruitment, genetic counseling or sample collection). 
Interviews lasted between 45-90 minutes and took place at a time and place convenient for 
interviewees. The semi-structured interviews were based on an interview guide (text box) 
covering the topics of the importance of research in pediatric oncology, introduction of WGS to 
families at the time of diagnosis as well as perceived challenges and dilemmas. All interviews were 
recorded and transcribed verbatim by research assistants with quality control by AW.  
Our questionnaire was developed by AB and AW based on concerns raised in interviews with 
parents (6) and healthcare professionals, to assess when it would be appropriate according to 
healthcare professionals to approach families about WGS. Prior to distribution, the questionnaire 
was revised based on comments by a sociologist and other members of the STAGING research 
team. The questionnaire was distributed via e-mail to 73 employees employed at either 
Rigshospitalet’s Department of Pediatric Oncology or at one of the Clinical Genetics Departments 
in Denmark. Invited employees included 45 nurses, 15 doctors and 13 clinical geneticists, including 
employees involved in STAGING. In addition to an oral reminder from senior pediatric oncologists, 
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reminders were distributed via e-mail 3 times after 4, 8 and 12 weeks from distribution. Of the 73 
employees who received the questionnaire, 54 employees participated rendering a participation 
rate of 74%. 19 (26%) did not participate in the study. All 15 (100.0%) pediatric oncologists, 27 of 
45 (60.0%) nurses, and 12 of the 13 (92.3%) clinical geneticists participated (Table 1). 
We carried out content analysis of the interview data generated (8) with both anthropologist and 
clinical geneticist reading each interview transcript carefully focusing on how informants view the 
introduction of WGS to families, the boundary between treatment/care and research, how to 
obtain informed consent and potential consequences of WGS. It has not been our intention to 
compare views across subgroups rather we have treated our informant group as a whole, i.e. 
those healthcare professionals who have played a role in the introduction of WGS into pediatric 
oncology in Denmark.  
Transcripts were read twice to ensure full data immersion, with a series of 3 coding meetings 
between AB and AW to discuss and agree on identified themes. Meetings were also used to relate 
the views and response patterns found in the interview transcripts to our own experiences in the 
clinic and in our interactions with clinicians (9).  
Study questionnaire responses were aggregated and divided based on gender, educational 
background, and age. We initially performed Chi2 tests in order to identify potential differences 
between groups, none of the analysis reached statistical significance, likely due to the small 
sample size, and we opted not to include these results. The questionnaire study was supplemental 
to our overall aim of exploring healthcare professionals’ views on the introduction of WGS into 
pediatric oncology. 
 
Results 
Doctor, researcher or both? 
WGS has been introduced into pediatric oncology in Denmark through the STAGING research 
project. All interviewees insisted that research is fundamental to the treatment of children with 
cancer, with a few suggesting that not gaining as much knowledge as possible from every single 
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patient was immoral. At the same time, research within pediatric oncology healthcare inevitably 
raises ethical challenges for professionals due to imbalances in doctor-patient relations. For 
families in crisis in a welfare state like Denmark, trust in authority and dependence prevails, 
particularly as regards their primary treating physician.  
So when you go into a family’s ward room, where you are both telling them about their child’s 
diagnosis and in the same breath introducing them to research, you have to be very careful in 
choosing your words. You have to consider very carefully what kind of power imbalance you are in the 
midst of (Pediatric Oncologist B)  
This imbalance can also reveal itself through what is actually said to families as physicians maintain 
a kind of ‘editorial power’ when it comes to dispensing information. Many doctors face an 
embedded conflict as they oftentimes have stakes in both the treatment provided and research 
conducted: 
At times I think I may ‘oversell’ research projects. Especially projects that I am an active part of. … 
Afterwards I’ll reflect on whether my presentation was fair or not and there are times where I’ve 
thought ‘that was borderline’, but I haven’t thought it was wrong... You do [as a doctor] have 
enormous power… At times I have thought that I've stood there explaining something where they... 
They say ‘yes’, but actually they don't know what they are saying ‘yes’ to. And I don't feel so good 
about that. I mean... I'm not trying to manipulate them into saying ‘yes’, because for me it is definitely 
legitimate to say ‘no’ …  On the other hand, some families might end up saying 'no' to something 
where I'm thinking "this would have been a really good opportunity for you"... So, there are times 
when we are left with a bitter taste in our mouths, wondering whether we have done the right thing 
(Pediatric Oncologist C) 
As described here, the lines between physician and researcher roles can get blurred, which raises 
questions about the possibility of undue influence, whereby the doctor’s own enthusiasm for a 
project risks swaying patients and their families’ views (10). Almost all interviewed pediatric 
oncologists agreed that this is an unavoidable consequence of the doctor-patient relationship, but 
also in any human relation: 
I don’t think we can escape this issue. You can try to reduce the consequences by being aware, 
humble and open about it. You could get someone not related to any part of the research project to 
provide information about the project, but then again they wouldn’t be able to explain it in sufficient 
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detail. And, as soon as you have gained sufficient knowledge you are a part of it (Pediatric Oncologist 
B)  
When asked about undue influence another doctor mulled over the idea of being two doctors 
informing families about research together, which he surmised might make both more conscious 
about the way they choose their words. He continued: 
…we have implemented this study because we want patients to participate. I think it’s okay to say ‘we 
hope you will consider it’ and that you want them to participate. But you can’t pressure them to do so 
(Pediatric Oncologist D) 
A project coordinating nurse noted that influence was indeed at times used as a way to move 
things along.  
When I have followed up with a family 3 or 4 times, I might ask them if they have any further 
questions. And sometimes I namedrop a certain doctor, and explain that this is his project, and that 
they can also ask him. It’s a bit subconscious I think, because I know they like him (Research 
Coordinator A) 
A final theme concerning doctor-patient/family relations in research recruitment that emerged 
out of our interviews was that of paternalism, and there seemed to be a shared sense that a 
degree of paternalism is inevitable.  
We [pediatric oncologists] have always thought in terms of our patients. It may well be because we 
fight so much by their side. But in all honesty, they are not ours, they are their own… So, there is a 
balance there, in that we should not become too paternalistic towards them (Pediatric Oncologist E)   
This doctor went on to describe an episode concerning a family that had requested more time 
before being presented with a specific project. The patient suddenly deteriorated, and the 
researchers reached out to the doctor asking her to talk to the family again as securing biological 
material at this stage would allow the family to participate later if the patient did not make it. This 
would be crossing a line for the doctor: 
This is the only patient where I have said ‘I can’t do this. This is unethical’. They have had a window at 
a less critical time. They have already been given the opportunity… But I have also wondered whether 
this was the right decision (Pediatric Oncologist E) 
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Meaningful informed consent to WGS-research  
Related to the question of imbalances in relations between healthcare professionals and their 
patients, is the question of meaningful informed consent (11). During the first weeks on an 
oncology ward, families must digest complex information about diagnostics, treatment plans, 
potential side effects, and prognoses, while additionally being introduced to 5-10 different 
research projects (6). Given this overload of information, communication is to a large extent 
‘based on trust’. However, pediatric oncologists are not always convinced that families have fully 
understood what has been asked of them: 
I do worry that there are people who would say ‘yes’ to something that they don’t understand. I mean, if I 
had just found out that my child will die or has a terminal diagnosis… I mean that’s what many people are 
thinking when they are told “your child has cancer”, they’re thinking “my child is going to die”. You shut 
things out at that point, I mean I think your brain shuts down… You can’t imagine anything worse. Going 
from there to giving informed consent to something as complex, well I guess I do have my doubts as to 
whether they are in a position to take it all in… (Pediatric Oncologist N)  
Oncologists are also cognizant of how families have come through the hospital doors. Some 
families have literally gone to the doctor concerned about a flu only to find out that their child has 
cancer on the same day, while others have been trying for months to find answers to explain their 
child’s symptoms before finally receiving the cancer diagnosis. Doctors try to navigate how much 
information a family can digest at any given time: 
… I do sometimes introduce research projects on day 1... But then there are other families where you can 
see that they are so affected that they won't have understood anything I’ve said even before they came 
here... I mean, they are not in a place where they can understand anything. And it is difficult then to 
inform them about any of our research projects. We ask them to consider very complicated things, really 
already on day 1, where it is probably almost unethical sometimes to ask them to consider such things. 
We're pretty much speaking in two different languages at that point ... And that is regardless of a families' 
educational background. I mean for me there is no difference whether I am presenting a research project 
to someone from social class 4 or social class 1 (Pediatric Oncologist C) 
While these factors are relevant for all research, some pediatric oncologists pointed out that they 
thought that WGS presented specific challenges because of the complexities involved. Before 
parents’ consent to STAGING, they go through genetic counseling during which potential 
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consequences of WGS including the risk of secondary findings are raised. Some practitioners were, 
however, unsure whether families are able to sufficiently grasp the potential consequences: 
I mean, I do think that the challenge with WGS is that it just is so difficult to grasp. It is true both for us, but 
perhaps even more so for your average person … say you were to find out that your child has a BRCA2 gene 
defect and will have an 80% risk of getting breast cancer or ovarian cancer. First, what if you find this out 
prenatally, should one say ‘no thanks’ to having a child with that gene defect? If they are born, should one 
offer them a mastectomy? When? When should we remove their ovaries? When is the right time and when 
is it too late? I mean, you know. And we as doctors, me – who tends to think mathematically – I find it very 
difficult. And that’s what then leads me to ask whether it is at all possible to give fully informed consent 
(Pediatric Oncologist D) 
Against this backdrop of practitioner reflections about difficulties in obtaining meaningful 
informed consent to WGS, in our questionnaire study 10% of employees found it appropriate to 
approach families about germline WGS at the time of diagnosis, half of all respondents found it 
appropriate during the first two weeks (23% during the first week and 21% during the second 
week), 40% found it appropriate during the first 4 weeks from diagnosis, and 6% thought it should 
be scheduled after one month from diagnosis (Table 1). Clinical geneticists opted for either 
introduction at diagnosis or during the first week (37%) or during week 4 or after (63%). For 
pediatric oncologists these numbers were 47% at diagnosis or during the first week, 13% during 
the second week from diagnosis and 40% during the first 4 weeks. No one opted for approach 
after the first month. Among nurses, 19% opted for approach at diagnosis and during the first 
week, 35% opted for approach during the second week, and 46% opted for approach during week 
4 or later (Figure 1). When subdividing according to gender, there was a tendency towards male 
employees preferring an earlier approach than women (there were no males among nurses). 
Although 10% of participating women and men found approach at diagnosis appropriate, 40% of 
males found it appropriate during the first week, compared to only 16.6% of women. Conversely, 
74% of women thought it appropriate during or after the second week following diagnosis, 
compared to 50% of men (Figure 1). 
A final theme to emerge around the obtaining of meaningful informed consent to WGS was that 
the introduction of WGS into the pediatric oncology clinic in Denmark is not only new for families, 
it is also new for pediatric oncologists, some of whom do not consider themselves sufficiently 
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equipped to answer all potential questions from families. This raised concerns about how an 
introduction of WGS into the clinic can be professionally supported: 
Well, I would say that the first challenge is that I am from exactly that generation which didn’t have much 
exposure to genetics, right? I’m also from that generation who didn’t have a computer in school. The last 
generation! So many of us doctors who are around my age, who work here, who are in their 40s or 50s, we 
don’t have much knowledge about it. At least not the technical knowledge and things like how sure we are 
about the findings, how uncertain the numbers are, etc. So, we lack specialized education, you could say, 
we lack knowledge about it (Pediatric Oncologist D) 
 
Potential Consequences and Utility 
Genetic counseling and testing have traditionally been performed weeks or months after a serious 
diagnosis. More recently, as in the case of STAGING, counseling and testing have moved closer to 
the time of diagnosis to allow for treatment options based on genetic predisposition. And while 
the clinical geneticists interviewed for this study were not specifically asked about this 
development, it often emerged. Some were nervous that families would agree to something out of 
fear of losing their child, others did not see the need for burdening families at such an ‘early 
stage’. Still others argued that minimizing information prior to genetic testing might be beneficial, 
and that testing should be a clinical decision and that doctors should provide in depth counseling 
only when results had revealed a predisposition syndrome. 
Guilt is omnipresent within genetics both as regards the choice to undergo genetic testing or not 
and in terms of ‘survivor’s guilt’, where family members not carrying the family’s pathogenic 
variant feel guilt over their ‘luck’ (12). As one clinical geneticist in the study put it parents always 
feel guilty if they have passed ‘bad’ genes on to their children. Yet, one of the pediatric oncologists 
we interviewed insisted that the issue of guilt is not specific to genetics: 
We may well risk taking families hostage in our search for answers [about cancer etiology] and guilt is 
a big part of that… But guilt is not confined to WGS. Choosing to enroll in a randomized treatment trial 
harbors the same risk of guilt, because if the child relapses, parents will think ‘is this my fault? I chose 
to enroll my child in this trial’ (Pediatric Oncologist B) 
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Another issue regarding WGS is that other family members risk gaining information that they have 
not asked for: 
When you get knowledge of a genetic mutation in the family you are forced to think in family 
relations. That is new to many patients. They often have contact with close relatives but not 
necessarily those further out in their family. That puts it into a whole other perspective; people you 
share genes and diseases with are sometimes strangers (Clinical Geneticist J) 
However, genetic testing may also give some families reassurance regarding thoughts they are 
already burdened by: 
I don’t think a couple who have had a child with cancer has ever thought ‘this will never return’ or 
‘now we are home safe’. But in this case, we will be able to say that ‘we have done everything we 
could and there is no increased risk’ whereas in the case of any findings we will be able to say ‘there is 
something genetic in your child’s DNA and now we can watch out for the cancers there is a greater 
risk of developing’. I think we take better care of these families through this (Clinical Geneticist K) 
When doing WGS there is a risk of running into secondary findings; that is genetic findings that 
were not of primary interest, but are none the less identified and assessed. However - as pointed 
out by one clinical geneticist – this is always a risk when patients come into contact with the 
healthcare system:  
Every time someone contacts a doctor they may end up diagnosed with something they didn’t expect. 
We may be looking for pneumonia but end up finding lung cancer... The important thing is that we as 
medical professionals’ follow-up when something pathogenic turns up (Clinical Geneticist K) 
Healthcare professionals’ views regarding families’ abilities to cope with genetic information 
differed. Some thought families would have difficulties understanding it, while others did not 
share that concern. One pediatric oncologist argued: 
They do risk being taken hostage, ending up with some information they didn't need to have. They 
may opt out of receiving those, but there are some findings that they cannot opt out of, so they 
receive those findings regardless. And that is taking them hostage to some degree... but such hostage 
taking is present in so much of the clinical and research work we do (Pediatric Oncologist B) 
If a genetic predisposition is found, enrollment in a relevant clinical surveillance program may be a 
consequence. Surveillance programs within pediatric oncology are however debated: 
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There could be some surveillance that would be different [for a child with a germline predisposition] 
to what we do now. Or for other family members. And it may be significant. But we need to be critical, 
we should not do all sorts of tests without knowing that it can benefit the patient… you risk 
stigmatization (Pediatric Oncologist L) 
There are screening programs that are well documented and can increase survival and decrease 
toxicities, but we don’t have a lot of these diseases yet… I am against screening, but I think we need to 
be hesitant regarding screenings that don’t make a difference (Pediatric Oncologist F) 
A specific point of disagreement involved how to handle patients diagnosed with Li Fraumeni 
syndrome, resulting in a significant lifetime risk of developing various and multiple primary 
cancers. Studies of the so-called Toronto protocol (13) suggest that comprehensive surveillance 
efforts are beneficial yet these studies have been highly debated within the community. Some 
pediatric oncologists touched upon this:   
For the patients with a TP53 mutation we’ve had discussions. Some think we should initiate excessive 
surveillance programs, which in my opinion is without scientific evidence in terms of reducing 
morbidity and mortality (Pediatric Oncologist L) 
For Li-Fraumeni patients, they have an increased risk of cancer, but we don’t know which cancer they 
will develop. And you don’t know whether it will occur and where. And that means that either you 
have to sleep in an MRI scanner for the rest of your life, or then you can live your life and be conscious 
of symptoms and act accordingly if they should arise (Pediatric Oncologist F) 
A competing argument was put forward by both clinical geneticists and pediatric oncologists. As 
one clinical geneticist put it: 
Over time we have found that genetic testing needs to be put up-front. That it is simply stupid to wait 
for the second tumor before you think that something may be wrong… You cannot offer a child the 
best standard of care if you don’t know what is waiting around the corner. It would be stupid to give 
irradiation therapy to a child who has a mutation that results in lower sensitivity to irradiation therapy 
and an increased risk of a secondary cancer … the more we know the better we are able to help 
(Clinical Geneticist K) 
 
Discussion 
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Through this combined qualitative and quantitative study we have explored the double-role held 
by many healthcare professionals within pediatric oncology i.e. working both in the clinic and in 
research. While this has been the case for many years by now, we have focused on how this 
double-role relates to the introduction of WGS into pediatric oncology. Primary concerns raised by 
healthcare professionals regards the potential of undue influence, obtaining meaningful informed 
consent, and the clinical utility of WGS. These concerns notwithstanding, 94% of respondents 
found it acceptable to approach families about WGS with the first month from the child’s 
diagnosis. In the following, we will discuss our findings in light of previous research as well as 
highlight strengths and weaknesses of this study.  
 
Influence – undue? 
Numerous dilemmas concerning autonomy, power imbalances, and consent rise out of the 
dependency in the doctor-patient relationships. These issues have been described by other 
previously (14), but with the introduction of WGS into the routine diagnostic care novel 
complexities arise. All pediatric oncologists interviewed for our study were acutely aware of this 
and reflected on the responsibilities this relationship engendered. At the same time there is an 
abiding sense among pediatric oncologists/clinical geneticists that research is completely 
fundamental to the medical care that is delivered, and an inherent sense of obligation to gain as 
much knowledge from every case of childhood cancer as possible to better the chance of survival 
and decrease morbidity for future patients. Our findings are supported by Dekking et al. who also 
found that “when informing families about research, [pediatric oncologists] sometimes felt a 
tension between motivating and being too persuasive” and that “research is considered a 
fundamental and indispensable characteristic of practice” (10). What these findings suggest is that 
there is a fading boundary between research and care within oncology (1). And this calls for active 
engagement in the clinic with ‘situated ethics’ (15) whereby healthcare practitioners reflect on 
and share those cases where, as one pediatric oncologist put it, “we are left with a bitter taste in 
our mouths, wondering whether we have done the right thing”. Distinguishing influence from 
undue influence, inducement or coercion requires dialogue and reflection on the part of 
practitioners. 
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One pediatric oncologist pointed out that it could be beneficial to see how communication may 
change if two colleagues informed families of research alongside each other, arguing that the 
presentation may be more measured if a colleague were present. This highlights an inherent 
tension; that doctors who have a personal stake in patients accepting participation in their study 
are also the people informing them thereof. Addressing this, another pediatric oncologist 
suggested that you have people not involved with the study inform patients and families about 
research projects. The problem, however, is that as soon as someone gets a certain level of insight 
into a project they would have a stake in it. And while it may be technically possible to get 
qualified candidates to include patients in the study it would be costly and difficult to implement 
as many biomedical research projects are complicated and require the person informing patients 
about the study to be educated within the biomedical field, to be able to give adequate 
information. While there is nothing new about such tension in medical research in the clinic, the 
introduction of WGS into pediatric oncology through research raises a number of dilemmas that 
are specific. 
 
Meaningful informed consent to WGS 
Informed consent is complex even in the best of circumstances, and as pointed out by numerous 
interviewees in the study, particularly complex when regarding WGS. Some pediatric oncologists 
had experienced that families had misunderstood elements when discussing the study after the 
genetic counseling session. This is a well-known issue within medicine and clinical genetics – that 
patients do not recall information given during a clinical or research consultation (16). Numerous 
interviewed pediatric oncologists pointed out that their own understanding of WGS is sparse 
making it difficult for them to help if patients had further questions. Scollon et al. also found that 
the communication provided by pediatric oncologists and clinical geneticists when returning 
results from exome sequencing were largely one-way communication lacked involvement of 
parents and patients (17). To improve understanding and recollection numerous suggestions have 
been made including having two inclusion sessions as a so called ‘two-tier model’ (11), educational 
sessions, follow-up interviews or questionnaires after the inclusion session. 
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Other suggestions could be to have patients (in this case parents) go through educational training 
to ensure they obtained the relevant knowledge. In drug trials it is good clinical practice to have 
patients repeat what they have been told by the informing doctor, in order to ensure that they 
have the level of knowledge that is required to handle taking the medication, being aware of side 
effects, etc. However, further educational sessions at a time when the patient is being treated for 
cancer, might be infeasible for families given their circumstances. Another option would be to do 
more general Q&A sessions for participating families allowing for further knowledge to be 
obtained. The benefit of implementing further educational training is to help participating patients 
and families be better prepared for eventualities. However, such requirements might risk families 
opting out, especially families from less-resourced social backgrounds. As a more feasible option, 
optional Q&A or educational sessions may be worth exploring to heighten the understanding of 
the complex information about risk, surveillance and secondary findings for both patients, families 
and healthcare professionals. On this note, it is worth mentioning that information regarding WGS 
includes information about secondary findings, which by their very nature are impossible to give 
an exhaustive presentation of. 
These findings stand somewhat in contrast to the findings from our questionnaire study in which 
healthcare professionals overwhelmingly supported introduction to WGS research within the first 
4 weeks after diagnosis. This might be because – as argued by one interviewee – the introduction 
process works ‘exactly because’ the treating physician is asked whether they deem a family ready 
for approach. Further educational interventions aimed at families do not seem to necessarily 
hinder approach during the first 4 weeks following diagnosis, indicating that the crisis that families 
are in, mentioned by some interviewees as a hindrance to meaningful informed consent, is seen to 
subside during the first weeks. Hence, further educational training may help address potential 
gaps in knowledge. This corresponds well with our previous findings in which we asked parents 
about their perspectives on participation in WGS research (6), and found varying views concerning 
the right time for approach, although the vast majority of interviewed parents had found an early 
approach acceptable (<4 weeks from diagnosis). However, as pointed out by a doctor in a study by 
Ardern-Jones et al. (18) of genetic testing at the time of cancer diagnosis, “nobody knows” what 
the right time to approach families is. 
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Smaller differences were seen between doctors (including pediatric oncologists and clinical 
geneticists) and nurses in our questionnaire. Doctors tended to approve of an earlier approach 
compared to nurses which might reflect the different duties of nurses and doctors: doctors are 
highly focused on treatment of the child with cancer (and, in our case, the potential for treatment 
adaptation based on WGS results), whereas nurses often take the role of general caretaker of the 
whole family. 
 
Utility  
Within the STAGING project, families are informed that inclusion will not alter the course of their 
child’s treatment but may – if a cancer predisposition syndrome is found – result in different forms 
of surveillance post-treatment. The nature of surveillance is controversial as some pediatric 
oncologists are concerned by its implications, which led to clashes between those critical of 
surveillance and proponents within the relatively small medical specialty of pediatric oncology in 
Denmark when STAGING was implemented. McCullough et al. found that neither doctors nor 
parents found whole exome sequencing to be an ethically disruptive technology when applied to 
pediatric cancer patients with solid tumors, and that parents overwhelmingly welcomed the 
additional knowledge in their decision making (19). On the other hand, Grove et al. (20) found 
numerous differences in opinion within healthcare professionals views, as participants disagreed 
on who would be responsible for sequencing results (laboratory, patient or healthcare provider) 
regarding what to disclose and at what indication, whether healthcare providers had sufficient 
knowledge to get informed consent from patients and deliver sequencing results. In our study, 
germline WGS emerged as a partially disruptive technology in the pediatric oncology clinic with 
differing practitioner views on its utility and relevance. History has shown how other so called 
‘ethically disruptive’ technologies have become mainstream in the clinic decades later (e.g. IVF). 
Yet, even if these practices have become mainstream, they still raise difficult ethical questions. 
The subject of much of modern medical ethics’ most difficult questions are the flip side of all the 
good that comes from new technologies. The same will likely apply to germline WGS. 
Roughly 100 families have received their results from WGS through the STAGING project, including 
both patients with pathogenic findings and patients without. Ongoing follow-up qualitative studies 
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will help us gain further knowledge into post-reporting family perspectives on participation as well 
as on genetic testing in the family and potential lifelong surveillance.  
 
Strengths and weaknesses 
A weakness of this study concerns the study set-up, in which the primary investigators AB and AW, 
also work within the STAGING study. And although AW is exactly engaged to address these issues, 
and regardless of anonymity, there is a risk that interviewees may have held some concerns back. 
Another weakness of the study concerns the questionnaire survey which was developed due to 
concerns raised by clinicians. Thus, the questionnaire was not validated through implementation 
in a pilot cohort prior to use in this study. Additionally, due to the convenience sampling used in 
this study, there is a risk that interviewees and respondents held a more positive view of the 
investigators and/or the STAGING study.  
The strengths of this study include the combination of the investigators’ experiences from their 
work on the ward, which included numerous contacts with clinicians, nurses, patients and parents 
(when approaching families about STAGING), in-depth interviews with - and survey data from - 
healthcare professionals. In addition, the scale of this study is a strength as key persons from all of 
Denmark’s Pediatric Oncology Departments and Clinical Genetics Departments involved in the 
study at the time, were interviewed and received a questionnaire.  
 
Conclusion 
Healthcare professionals within pediatric oncology and genetics in Denmark are aware of the 
dilemmas caused by the intertwinement of clinical work and research. Informed consent poses a 
challenge regarding germline WGS, as patients cannot be fully informed of all potential outcomes 
(primary or secondary). Overall, the majority of participating healthcare professionals support 
approaching families within the first 4 weeks from diagnosis. Interviewees advocate for further 
education of families participating in WGS research and call for continued training of themselves 
on the subject of WGS. Healthcare professionals are divided in their views on surveillance. 
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Figure Legends: 
Figure 1: Healthcare professional’s opinion of what constitutes the appropriate time from 
diagnosis to approach about STAGING as distributed according to job title, gender, and age   
*2 respondents did not fill out the age range question  
 
Table 1: Questionnaire distributed to healthcare professionals. Distribution of answers are given 
under each question.  
 
Text Box: Questions semi-structured interview guide 
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Table 1: Questionnaire distributed to healthcare professionals.   
Question     Answer, n (%) 
1. Employment: Are you? 
Doctor within pediatric oncology  15 (28%)  
Nurse within pediatric oncology  27 (50%) 
Clinical geneticist   12 (22%) 
2. Place of employment: where in Denmark are you employed? 
Aalborg University Hospital  1 (2%) 
Aarhus University Hospital  3 (6%) 
Odense University Hospital  3 (6%) 
Copenhagen University Hospital (Rigshospitalet) 46 (87%) 
3. Gender: are you? 
Male    10 (19%) 
Female    43 (81%) 
4. Age: I am… 
<40 years old   22 (42%) 
40-50 years old   16 (30%) 
>50 years old   13 (25%) 
I do not wish to say   2 (4%) 
5. In a child with cancer, where there is no suspicion of a cancer predisposition syndrome or 
family pedigree with massive cancer disposition, when do you think it appropriate to ask a 
family to participate in STAGING? 
In connection with the diagnostic interview  
or the day after   5 (10%) 
During the first week from diagnosis  12 (23%) 
During the second week from diagnosis 11 (21%) 
During week 3 or 4 from diagnosis  21 (40%) 
Later    3 (6%) 
6. The participation rate in the STAGING study is high (>90% have agreed to participate). The 
families have not until now been approached earlier than 2 days after their diagnostic 
interview. Do you think the high participation rate, is due to the fact that families are not 
asked on the day of diagnosis?  
Yes    26 (50%) 
No    13 (25%) 
I do not know    13 (25%) 
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Text box: Questions semi-structured interview guide 
 
1. Why is it important to carry out as much research as you do on the pediatric oncology ward? 
2. What do you need to be mindful of when you approach families about participation in a research 
project? 
3. What do you see as some of the specific or important ethical issues that whole genome sequencing gives 
rise to for families? 
4. In which ways do you envisage genetic information will be relevant for you as a practitioner? 
 
